Admit it -- you've probably at least considered buying Illumina stock since the company announced its acquisition of Solexa. Motley Fool has an article on Illumina's earnings with a quick analysis of the company's numbers and position in the competitive landscape. One interesting tidbit the story points out: "its bottom line was eroded by $8.7 million" thanks to the eagerness with which employees have been cashing in their stock options.

 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers describe a way to share data while keeping it secure, Agence France Presse reports.

In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.

India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.

A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.